RS95904A - Tri -substituted heteroaryls and methods for making and using the same - Google Patents

Tri -substituted heteroaryls and methods for making and using the same

Info

Publication number
RS95904A
RS95904A YU95904A YUP95904A RS95904A RS 95904 A RS95904 A RS 95904A YU 95904 A YU95904 A YU 95904A YU P95904 A YUP95904 A YU P95904A RS 95904 A RS95904 A RS 95904A
Authority
RS
Serbia
Prior art keywords
tri
making
methods
same
substituted heteroaryls
Prior art date
Application number
YU95904A
Other languages
English (en)
Inventor
Wen-Cherng Lee
Lihong Sun
Feng Shan
Claudio Chuaqui
Zhongli Zheng
Russell Petter
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of RS95904A publication Critical patent/RS95904A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenja formule (I) poseduju neočekivano veliki afinitet prema Alk 5 i/ili Alk 4, i mogu biti korisni kao njihovi antagonisti za prevenciju i/ili lečenje brojnih oboljenja, uključujući poremećaje vezivnog tkiva. U jednom rešenju, predmetni pronalazak obuhvata jedinjenje opšte formule (I).
YU95904A 2002-04-04 2003-04-04 Tri -substituted heteroaryls and methods for making and using the same RS95904A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36979302P 2002-04-04 2002-04-04
PCT/US2003/010440 WO2003087304A2 (en) 2002-04-04 2003-04-04 Tri-substituted heteroaryls and methods of making and using the same

Publications (1)

Publication Number Publication Date
RS95904A true RS95904A (en) 2006-10-27

Family

ID=29250467

Family Applications (1)

Application Number Title Priority Date Filing Date
YU95904A RS95904A (en) 2002-04-04 2003-04-04 Tri -substituted heteroaryls and methods for making and using the same

Country Status (19)

Country Link
US (1) US7612094B2 (sr)
EP (1) EP1499308A4 (sr)
JP (1) JP2005527590A (sr)
KR (1) KR20040094908A (sr)
CN (1) CN100448868C (sr)
AR (1) AR039241A1 (sr)
AU (1) AU2003228446B2 (sr)
CA (1) CA2480860A1 (sr)
EA (1) EA010418B1 (sr)
IL (1) IL164295A0 (sr)
IS (1) IS7475A (sr)
MX (1) MXPA04009546A (sr)
NO (1) NO20044779L (sr)
NZ (1) NZ536202A (sr)
PL (1) PL373502A1 (sr)
RS (1) RS95904A (sr)
UA (1) UA81624C2 (sr)
WO (1) WO2003087304A2 (sr)
ZA (1) ZA200407902B (sr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
ES2325687T3 (es) * 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
EA200500354A1 (ru) 2002-09-18 2005-10-27 Пфайзер Продактс Инк. Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
DE60330362D1 (de) 2002-09-18 2010-01-14 Pfizer Prod Inc Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
MXPA05002982A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf).
AP2005003262A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
WO2005065691A1 (en) * 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
NZ549003A (en) 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
AU2005280168A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as TGF-beta inhibitors
WO2006028029A1 (ja) * 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
JP2008516962A (ja) * 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2007076086A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Tricyclic spiro compounds useful as transforming growth factor modulators
EP2083863B1 (en) 2006-10-03 2015-03-18 Genzyme Corporation Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
WO2009009059A1 (en) * 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2274300A2 (en) * 2008-03-21 2011-01-19 Novartis AG Novel heterocyclic compounds and uses therof
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20100087486A1 (en) * 2008-05-30 2010-04-08 Hiroshi Nakamura Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
EP2419105A4 (en) * 2009-04-17 2012-09-12 Summa Health Systems Llc USE OF TRANSFORMATION OF GROWTH FACTOR B RECEPTOR INHIBITORS TO SUPPRESS OCULAR HEALING
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
PL2731949T3 (pl) 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
RU2019119893A (ru) 2013-03-14 2019-08-09 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SI3104847T1 (sl) 2014-02-07 2021-07-30 Tamogatott Kutatoscoportok Irodaja Nova uporaba spojin SIGMA-1 receptor agonista
US10842794B2 (en) 2014-02-07 2020-11-24 Támogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3914594A4 (en) * 2019-01-22 2022-09-14 Bisichem Co., Ltd. RING-FUSED HETEROARYL COMPOUND USED AS ALK4/5 INHIBITOR
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
MX2023000519A (es) 2020-07-15 2023-02-13 Chiesi Farm Spa Derivados de pirido-oxazina-amino como inhibidores de alk5.
KR20230051500A (ko) 2020-07-15 2023-04-18 키에시 파르마슈티시 엣스. 피. 에이. Alk5 억제제로서 피리다진일 아미노 유도체
EP4182322B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
WO2022136221A1 (en) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法
CN114105975A (zh) * 2021-02-25 2022-03-01 无锡海伦生物科技有限公司 一种[1,2,4]三氮唑[1,5-a]吡啶-6-甲醛的合成方法
AR127108A1 (es) 2021-09-21 2023-12-20 Chiesi Farm Spa Derivados de amino piridazinilo como inhibidores de alk5
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
AU1422392A (en) * 1991-03-22 1992-10-21 Nippon Soda Co., Ltd. 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
DK64592D0 (da) * 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US6369068B1 (en) * 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5854276A (en) 1995-06-29 1998-12-29 Fujisawa Pharmaceutical Co., Ltd. Substance WF16616, process for production thereof, and use thereof
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5756499A (en) 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
JP2000504013A (ja) 1996-02-01 2000-04-04 スミスクライン・ビーチャム・コーポレイション エンドセリンレセプターアンタゴニスト
EP1005343A1 (en) * 1996-03-08 2000-06-07 Smithkline Beecham Corporation Use of csaid?tm compounds as inhibitors of angiogenesis
JP2000506532A (ja) * 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
JP2000507545A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en) * 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) * 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
DE69733135T2 (de) * 1996-06-10 2006-03-02 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100568438B1 (ko) 1997-04-24 2006-04-07 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 치환된 이미다졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
JP4380803B2 (ja) * 1997-06-12 2009-12-09 アベンテイス・フアルマ・リミテツド イミダゾリル−環式アセタール
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6040320A (en) * 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6562832B1 (en) * 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR017219A1 (es) * 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
CA2341370A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
ATE258055T1 (de) * 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
ES2244231T3 (es) * 1998-12-25 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. Derivados de aminopirazol.
ES2197092T3 (es) * 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
DE60020560T2 (de) 1999-06-03 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. Substituierte pyrazol-derivate
CA2373883A1 (en) * 1999-07-02 2001-01-11 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
US20030109428A1 (en) * 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
JP2003535062A (ja) * 2000-06-01 2003-11-25 メルク エンド カムパニー インコーポレーテッド Ｊｎｋ阻害剤としての（二置換フェニル）ピリミジニルイミダゾール誘導体の使用
JP2004501913A (ja) * 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
US6755497B2 (en) * 2000-09-26 2004-06-29 Canon Kabushiki Kaisha Ink-jet printing apparatus, control method thereof, and data processing apparatus and method
JP2002114780A (ja) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
JP4217480B2 (ja) * 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
EP1363904A1 (en) * 2001-02-02 2003-11-26 Glaxo Group Limited Pyrazoles as tgf inhibitors
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US6727364B2 (en) * 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
EP1406573A4 (en) * 2001-06-07 2005-03-30 Skinmedica Inc CONDITIONED CELL CULTURE MEDIA AND ITS USES
US7300442B2 (en) * 2001-07-11 2007-11-27 Daniel Cherfas Method of destroying formations in a body
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
ES2325687T3 (es) * 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
EA200500354A1 (ru) * 2002-09-18 2005-10-27 Пфайзер Продактс Инк. Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)

Also Published As

Publication number Publication date
US20060063809A1 (en) 2006-03-23
KR20040094908A (ko) 2004-11-10
IL164295A0 (en) 2005-12-18
WO2003087304A3 (en) 2004-07-22
PL373502A1 (en) 2005-09-05
AU2003228446A1 (en) 2003-10-27
CN100448868C (zh) 2009-01-07
IS7475A (is) 2004-09-28
EA010418B1 (ru) 2008-08-29
EP1499308A4 (en) 2006-05-24
JP2005527590A (ja) 2005-09-15
ZA200407902B (en) 2005-09-22
AR039241A1 (es) 2005-02-16
UA81624C2 (ru) 2008-01-25
EA200401309A1 (ru) 2005-08-25
NZ536202A (en) 2009-08-28
US7612094B2 (en) 2009-11-03
MXPA04009546A (es) 2005-01-25
NO20044779L (no) 2005-01-04
AU2003228446B2 (en) 2009-08-06
WO2003087304A2 (en) 2003-10-23
CA2480860A1 (en) 2003-10-23
EP1499308A2 (en) 2005-01-26
CN1658866A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
RS20050200A (en) Pyrazolopyridines and methods of making and using the same
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
HK1083838A1 (en) A2a adenosine receptor antagonists
HK1068136A1 (en) Muscarinic antagonists
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
GB0325956D0 (en) Novel compounds
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
MY135841A (en) Novel benzodioxoles
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
BRPI0414678A (pt) forma polimórfica de 3-fenil sulfonil-8-piperazin-1-il quinolina
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
MXPA04004980A (es) Antagonistas del receptor ccr-3.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
HU0201195D0 (sr)
MXPA03010325A (es) Benzoilciclohexenonas substituidas y su uso como agentes herbicidas.